Pancreatic cancer, for example: 3 in 100 alive after five years if found late, 44 if found early.1
Scroll ↓
Tumours shed DNA into the blood
Reading those fragments tells you about the tumour without a biopsy. This is the basis of liquid biopsies.
One tube of blood is often too little
It holds about 6,000 genome copies, and some small cancers shed less than 1 tumour copy in 10,000.2 We can't take a cup of blood.
What if we just had more material?
Urine carries cell-free DNA, tumour DNA included
The kidneys filter the blood and pass short DNA fragments into the urine.3
Accessible, non-invasive, larger volumes.
A cup of urine holds 50× more cell-free DNA than a tube of blood
300 mL against 4 mL.4 At 1 tumour copy in 10,000, the tube expects 0.6 copies. The cup, 30.
We break the extraction wall
A whole cup goes in. Pure, concentrated cell-free DNA comes out, ready for any test.
A 6% chance becomes 89% or more
With enough volume, urine could contain the needed relevant tumor molecules consistently5
Shown in bladder cancer. Next: pancreatic and prostate cancer
PRECIS-BC, our running trial with Radboudumc, asks whether a urine test can spare the bladder. About the trial ↗
First pancreatic data: Q2 2027.
Liquid biopsy is growing. There is much more to reach
Testing grew 68% in a year.6 In a French screening trial, a urine kit mailed home nearly doubled participation.7Why now →
We move fast
A trial running, a patent-pending device.
Team
In Delft, on the Biotech Campus.
Eric van der ToornCo-founder, CEOBioinformatician and AI researcher
David Calderón FrancoCo-founder, CTOA leading expert in cfDNA isolation
Thomas AbeelCo-founder, CSO. Associate professorLeading AI bioinformatician
Harshitha HanjiBusiness developmentBiotech partnerships and grant funding
Gonçalo MacedoResearch scientistQuality and regulatory
Advisors
Each has taken a life-science company to a sale.
Prof. Jack SchalkenUrology professor. Co-founded NovioGendix, sold to MDxHealth
Joris SchuurmansCEO SkylineDx. Sold Cergentis in 2022. Before: Biocartis, MyCartis
Jan Groen, PhDChaired Vesica Health to its 2026 sale. Ex-CEO MDxHealth
Supported by
Health Holland funds the PRECIS-BC trial (TKI-LSH SME Call 2025). Provincie Zuid-Holland: MIT feasibility study. Kansen voor West is co-funded by the European Union (EFRO).